Exhibit 99.1

CESCA THERAPEUTICS ANNOUNCES MARCUM LLP AS THE COMPANY'S NEW INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Rancho Cordova, CA, June 1, 2015 -- Cesca Therapeutics Inc. (Nasdaq: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has appointed Marcum LLP as its independent registered public accounting firm. Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States.

Robin C. Stracey, Cesca's Interim CEO & Director commented, "We looked at the team, service offerings, reputation and pricing for several high profile independent public accounting and advisory firms across the United States and were more than impressed with Marcum.  We look forward to working with them to quickly bring Cesca back into full compliance with SEC and Nasdaq reporting requirements and will update stockholders as we progress toward that goal."

About Marcum LLP:

Marcum LLP is one of the largest independent registered public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets.

About Cesca Therapeutics Inc.

·	SurgWerks™; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:

·	Cell harvesting

·	Cell processing and selection

·	Cell diagnostics

·	Cell delivery

·	CellWerksTM; a proprietary stem cell laboratory kit for the processing of target cells used in the treatment of oncological and hematological disorders.

·	The AutoXpress® (AXP); a proprietary automated device, along with  companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.

·

The MarrowXpress® (MXP); a derivative product of the AXP and its accompanying disposable bag set, for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control optical sensors that volume-reduces blood from bone marrow to a user defined volume in 30 minutes while retaining over 90% of mononuclear cells (MNCs).

·	The Res-Q™ 60 (Res-Q); a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).

·	The BioArchive® System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.

Forward Looking Statement:

The statements contained herein may include statements of future expectations and other forward looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements, including FDA approval, timing of the Company's submission of IDE applications, or amendments to such applications, and outcomes from such submissions. Further, clinical trial outcomes are not predictable, and results may vary from the Company's expectations, including the start of any such clinical trials, patient follow up issues, and costs associated with such trials. Further description of other risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.